Nicola A Hanania
Overview
Explore the profile of Nicola A Hanania including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
295
Citations
7522
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ortiz J, Staggers K, Adrish M, Hanania N, Wu T
Respir Med
. 2025 Mar;
240:108032.
PMID: 40058666
Background: Asthma disproportionately affects vulnerable populations. Safety net hospitals (SNHs) manage a significant proportion of these patients. Despite the assumption that patients in SNHs have more severe asthma, little is...
2.
Vogelmeier C, Rabe K, Bhatt S, Hanania N, Bafadhel M, Christenson S, et al.
Respir Med
. 2025 Mar;
:108015.
PMID: 40024335
Background: The body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index predicts 5-year mortality risk in chronic obstructive pulmonary disease (COPD); higher scores predict worse outcomes. Dupilumab, a...
3.
Domingo C, Busse W, Hanania N, Ertugrul M, Millette L, Maio-Twofoot T, et al.
Allergy
. 2025 Feb;
PMID: 39963805
Asthma is a chronic airway inflammatory disorder, affecting over 350 million people worldwide, with allergic asthma being the most common form of the disease. Allergic asthma is characterized by a...
4.
Bhatt S, Rabe K, Hanania N, Vogelmeier C, Bafadhel M, Christenson S, et al.
Lancet Respir Med
. 2025 Feb;
13(3):234-243.
PMID: 39900091
Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation. We aimed to characterise the efficacy...
5.
Bhatt S, Rabe K, Hanania N, Vogelmeier C, Bafadhel M, Christenson S, et al.
Chest
. 2025 Feb;
PMID: 39894389
Background: Patient-reported outcomes should be considered alongside clinical assessments to guide therapy for COPD. Research Question: Does add-on dupilumab treatment improve health-related quality of life and respiratory symptoms in patients...
6.
Hanania N, Celli B
Chronic Obstr Pulm Dis
. 2024 Dec;
12(1):82-92.
PMID: 39688360
Chronic obstructive pulmonary disease (COPD) is a highly prevalent inflammatory lung condition characterized by chronic respiratory symptoms and airflow obstruction that often leads to diminished quality of life. Nonpharmacologic management...
7.
Jesenak M, Bobcakova A, Bobcakova D, Djukanovic R, Gaga M, Hanania N, et al.
Chest
. 2024 Dec;
PMID: 39672229
Asthma is a common multifaceted respiratory disease with a major impact on quality of life. Despite increased insights into mechanisms underlying various asthma phenotypes and endotypes and the availability of...
8.
Wang J, Bose S, Holbrook J, Nan L, Eakin M, Yohannes A, et al.
Chronic Obstr Pulm Dis
. 2024 Dec;
12(1):33-42.
PMID: 39636058
Background: Most studies on mental health among individuals with chronic obstructive pulmonary disease (COPD) utilize screening questionnaires, which detect psychiatric , but cannot be used to depression/anxiety disorders. We utilized...
9.
Celli B, Anzueto A, Singh D, Hanania N, Fabbri L, Martinez F, et al.
Chest
. 2024 Dec;
PMID: 39631681
Topic Importance: COPD is a complex, heterogeneous lung disease characterized by persistent airflow limitation secondary to airways and parenchymal abnormalities, and respiratory symptoms, including dyspnea, fatigue, chronic cough, and sputum...
10.
Raju S, Sierra P, Tejwani V, Staggers K, McCormack M, Villareal D, et al.
Diabetes Care
. 2024 Nov;
48(1):143-148.
PMID: 39571139
Objective: Insulin resistance (IR) may be a risk factor for lung disease, but objective evidence is limited. We sought to define the relationship of longitudinal IR with radiographic imaging outcomes...